CTEPH
MCID: CHR466
MIFTS: 41

Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Categories: Blood diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Chronic Thromboembolic Pulmonary Hypertension

MalaCards integrated aliases for Chronic Thromboembolic Pulmonary Hypertension:

Name: Chronic Thromboembolic Pulmonary Hypertension 53 37 72
Cteph 53

Classifications:



External Ids:

KEGG 37 H01622
UMLS 72 C2363973

Summaries for Chronic Thromboembolic Pulmonary Hypertension

KEGG : 37
Chronic thromboembolic pulmonary hypertension (CTEPH) is classified as group 4 pulmonary hypertension (PH) by the World Health Organization. It is a rare, but underdiagnosed, complication of acute pulmonary embolism (PE) resulting from occlusion of large pulmonary arteries with a fibrothrombotic material and in many cases, the development of a distal vessel arteriopathy that closely mimics pulmonary arterial hypertension. While the pathogenesis of CTEPH is not entirely understood, the primary pathophysiology appears to be related to an initial thrombotic event followed by both inadequate thrombus resolution and secondary arteriopathy. Several risk factors for development of CTEPH have been found, including the size of the initial PE, splenectomy, chronic inflammatory conditions, and indwelling catheters and cardiac pacemaker leads. There is however an increased incidence of elevated factor VIII levels in CTEPH, and this finding persists after treatment. However, none of these findings explain the development of CTEPH in the majority of patients affected by this disease.

MalaCards based summary : Chronic Thromboembolic Pulmonary Hypertension, also known as cteph, is related to pulmonary hypertension and pulmonary embolism. An important gene associated with Chronic Thromboembolic Pulmonary Hypertension is FGA (Fibrinogen Alpha Chain), and among its related pathways/superpathways are Collagen chain trimerization and Platelet Aggregation Inhibitor Pathway, Pharmacodynamics. The drugs Tissue Plasminogen Activator and Plasminogen have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

NIH Rare Diseases : 53 Chronic thromboembolic pulmonary hypertension (CTEPH) is a unique pulmonary vascular disease caused by chronic block of the major lung arteries. Signs and symptoms commonly include progressive breathing difficulties (dyspnea) on exertion, fatigue, palpitations, loss of consciousness (syncope), or swelling (edema). The disease may appear a few months or many years after the sudden blockage in a lung artery by a blood clot (acute pulmonary embolism). However, up to 60% of patients have no history of acute pulmonary embolism. Some people with this disease may have clotting problems. Research suggests there may be a genetic predisposition leading to abnormal vascular healing after pulmonary embolism in susceptible individuals, but no specific gene mutations have been identified in CTEPH. Curative treatment is done with pulmonary endarterectomy (a surgery that removes the blood clots in the lungs), and more recently by pulmonary balloon angioplasty (a procedure that opens up the vessels of the lung and increases blood flow).

Related Diseases for Chronic Thromboembolic Pulmonary Hypertension

Diseases related to Chronic Thromboembolic Pulmonary Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 193)
# Related Disease Score Top Affiliating Genes
1 pulmonary hypertension 31.6 NPPB EDN1 BMPR2
2 pulmonary embolism 31.3 NPPB F2 CRP
3 pericardial effusion 30.7 NPPB CRP
4 pulmonary hypertension, primary, 1 30.5 NPPB FGA EDN1 BMPR2
5 dysfibrinogenemia 30.4 FGA F2
6 cardiac tamponade 30.4 NPPB F2
7 thrombophilia due to activated protein c resistance 30.3 FGA F2
8 aortic valve disease 2 30.2 NPPB CRP
9 patent foramen ovale 30.0 FGA F2
10 homocysteinemia 30.0 F2 CRP
11 thrombocytosis 30.0 F2 CRP
12 eisenmenger syndrome 29.9 EDN1 BMPR2
13 sleep apnea 29.6 NPPB EDN1 CRP
14 pulmonary edema 29.4 NPPB F2 EDN1 CRP
15 portal hypertension 29.2 F2 EDN1 BMPR2
16 systemic scleroderma 29.1 EDN1 CRP
17 kidney disease 28.9 NPPB EDN1 CRP
18 vascular disease 28.7 FGA F2 EDN1 CRP BMPR2
19 arteries, anomalies of 28.6 NPPB EDN1 CRP BMPR2
20 coronary artery anomaly 28.5 NPPB F2 EDN1 CRP
21 pulmonary hypertension, chronic thromboembolic, without deep vein thrombosis 12.3
22 cardiac arrest 10.8
23 tricuspid valve insufficiency 10.5
24 antiphospholipid syndrome 10.5
25 thrombophilia due to thrombin defect 10.5
26 lung disease 10.5
27 respiratory failure 10.4
28 thrombosis 10.4
29 thrombophilia 10.4
30 syncope 10.4
31 pulmonary disease, chronic obstructive 10.3
32 hydrocephalus 10.3
33 hemopericardium 10.3
34 pulmonary venoocclusive disease 10.3
35 connective tissue disease 10.3
36 vasculitis 10.3
37 congenital hydrocephalus 10.3
38 intracranial hypertension 10.3 FGA F2
39 afibrinogenemia 10.2 FGA F2
40 afibrinogenemia, congenital 10.2 FGA F2
41 pulmonary venoocclusive disease 1, autosomal dominant 10.2
42 inflammatory bowel disease 10.2
43 hepatic veno-occlusive disease 10.2
44 sarcoma 10.2
45 hypothyroidism 10.2
46 spindle cell sarcoma 10.2
47 mediastinitis 10.2
48 heritable pulmonary arterial hypertension 10.2
49 fibrosing mediastinitis 10.2
50 malignant otitis externa 10.2 F2 CRP

Graphical network of the top 20 diseases related to Chronic Thromboembolic Pulmonary Hypertension:



Diseases related to Chronic Thromboembolic Pulmonary Hypertension

Symptoms & Phenotypes for Chronic Thromboembolic Pulmonary Hypertension

MGI Mouse Phenotypes related to Chronic Thromboembolic Pulmonary Hypertension:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.35 BMPR2 CRP EDN1 F2 FGA
2 homeostasis/metabolism MP:0005376 9.1 BMPR2 CPB2 CRP EDN1 F2 FGA

Drugs & Therapeutics for Chronic Thromboembolic Pulmonary Hypertension

Drugs for Chronic Thromboembolic Pulmonary Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Tissue Plasminogen Activator Phase 4
2 Plasminogen Phase 4
3
Selexipag Approved Phase 3 475086-01-2
4
Riociguat Approved Phase 3 625115-55-1
5
Treprostinil Approved, Investigational Phase 3 81846-19-7 6918140 54786
6
Ambrisentan Approved, Investigational Phase 3 177036-94-1 6918493
7 Calamus Phase 3
8 Endothelin A Receptor Antagonists Phase 3
9 Endothelin Receptor Antagonists Phase 3
10 Antihypertensive Agents Phase 3
11 Xenon Experimental Phase 2 7440-63-3
12 Fluorodeoxyglucose F18 Phase 2
13 Radiopharmaceuticals Phase 2
14 Central Nervous System Depressants Phase 2
15 Anesthetics, General Phase 2
16 Anesthetics Phase 2
17 Anesthetics, Inhalation Phase 2
18
Iloprost Approved, Investigational Phase 1 78919-13-8 6443959
19
Nitric Oxide Approved Phase 1 10102-43-9 145068
20
Heparin Approved, Investigational 9005-49-6 46507594 772
21
Phylloquinone Approved, Investigational 84-80-0
22
Edoxaban Approved 480449-70-5
23
Thrombin Approved, Investigational
24
Rivaroxaban Approved 366789-02-8
25
Warfarin Approved 81-81-2 6691 54678486
26
Macitentan Approved 441798-33-0
27
Bosentan Approved, Investigational 147536-97-8 104865
28
Tadalafil Approved, Investigational 171596-29-5 110635
29
Iodine Approved, Investigational 7553-56-2 807
30
Streptokinase Approved, Investigational 9002-01-1
31
Dopamine Approved 51-61-6, 62-31-7 681
32
Methamphetamine Approved, Illicit 537-46-2 10836
33
Serine Approved, Nutraceutical 56-45-1 5951
34
Menadione Approved, Nutraceutical 58-27-5 4055
35
Calcium Approved, Nutraceutical 7440-70-2 271
36 Menaquinone Investigational 1182-68-9
37 Tezosentan Investigational 180384-57-0
38 Antiviral Agents
39 Deoxyglucose
40 Antimetabolites
41 Antibodies
42 Immunoglobulins
43 Autoantibodies
44
protease inhibitors
45 HIV Protease Inhibitors
46 Coagulants
47 Serine Proteinase Inhibitors
48 Antithrombin III
49 Vitamins
50 Antifibrinolytic Agents

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety Evaluation of Low Dosage of Recombinant Tissue Plasminogen Activator (rt-PA) in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China Completed NCT00781378 Phase 4 rt-PA;rt-PA
2 Efficacy and Safety Evaluation of 12-h and 2-h Urokinase Regimes in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China Completed NCT00799968 Phase 4 Urokinase;Urokinase
3 Influence of Respiratory and Exercise Therapy on Oxygen Uptake, Quality of Life and Right Heart Function in Chronic Thromboembolic Pulmonary Hypertension After Thromboendarterectomy Unknown status NCT01393327 Phase 3
4 Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Completed NCT00313222 Phase 3 bosentan
5 Long-term Open-label Extension Study in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Who Completed Protocol AC-052-366 (BENEFIT, NCT00313222) Completed NCT00319111 Phase 3 bosentan
6 Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Completed NCT00855465 Phase 3 Riociguat (Adempas, BAY63-2521);Placebo
7 Effect of Long-term Oxygen Therapy on Exercise Capacity and Quality of Life in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension Completed NCT01884012 Phase 3
8 A Prospective, Multicenter, Open-label, Single Arm, Phase III Study to Assess the Efficacy and Safety of Macitentan (ACT-064992) in Subjects With Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Recruiting NCT03809650 Phase 3 macitentan 10 mg
9 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Group-sequential, Adaptive, Phase 3 Study With Open-label Extension Period to Assess the Efficacy and Safety of Selexipag as an add-on to Standard of Care Therapy in Subjects With Inoperable or Persistent/Recurrent After Surgical and/or Interventional Treatment Chronic Thromboembolic Pulmonary Hypertension Recruiting NCT03689244 Phase 3 Selexipag;Placebo
10 CHANGE-MRI (CTEPH DIAGNOSIS Europe - MRI) Recruiting NCT02791282 Phase 3
11 A Double Blind Controlled Clinical Study to Investigate the Efficacy and Tolerability of Subcutaneous Treprostinil Sodium in Patients With Severe Non-operable Chronic Thromboembolic Pulmonary Hypertension (CTREPH) Active, not recruiting NCT01416636 Phase 3 Treprostinil sodium
12 Long-term Extension, Multicentre, Multi-international Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Active, not recruiting NCT00910429 Phase 3 Riociguat (Adempas, BAY63-2521)
13 A Randomised, Multicentre, Double-Blind, Placebo-Controlled Study Of Ambrisentan In Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Terminated NCT01884675 Phase 3 Ambrisentan 5 mg;Placebo
14 An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Terminated NCT01894022 Phase 3 Ambrisentan 5 mg
15 Randomized Pilot Trial of Interventional Treatment of Residual Pulmonary Hypertension in Patients After Pulmonary Thromboendarterectomy Unknown status NCT02745106 Phase 2
16 Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel-group, 24-week Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension Completed NCT02021292 Phase 2 Macitentan;Placebo
17 Evaluation of Right Ventricular Function and Metabolism Following Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension- Images of Rio Completed NCT02094001 Phase 2
18 Effect of Short-term Oxygen Therapy on Cardiopulmonary Exercise Capacity in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension Completed NCT01748474 Phase 2
19 A Multicenter, Non-randomized, Non-blinded, Noncontrolled Study to Investigate the Impact of Multiple Doses of BAY 63-2521 on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Pulmonary Hypertension in a 12-week 3 Times a Day Individual Dose Titration Scheme Completed NCT00454558 Phase 2 Riociguat (Adempas, BAY63-2521)
20 A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multicentre, Prospective Study to Assess Efficacy of Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy With High Preoperative Pulmonary Vascular Resistance Recruiting NCT03273257 Phase 2 Riociguat;Placebo
21 Non-Invasive Diagnosis of Pulmonary Vascular Disease Using Inhaled 129Xe Magnetic Resonance Imaging Recruiting NCT03078192 Phase 2 GE-141, Hyperpolarized 129Xenon gas
22 Long Term, Multicenter, Single-arm, Open-label Extension Study of the MERIT-1 Study, to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Active, not recruiting NCT02060721 Phase 2 Macitentan
23 Cell Proliferation in Pulmonary Hypertension. FDG-PET Comparison Between Patients and Healthy Subjects Active, not recruiting NCT02886793 Phase 1, Phase 2 fludeoxyglucose
24 Compassionate Use of Catheter Thrombectomy (Aspirex 11F) in Patients With Massive Pulmonary Embolism Terminated NCT00314002 Phase 1, Phase 2
25 A Non-randomized Two Part Multi-Center, Open-label, Single Dose Trial With an Escalation Part in Untreated PAH and CTEPH Patients (Part A), Followed by a Parallel Group Part in Untreated and Pre-treated Patients With PAH and CTEPH (Part B) to Investigate the Safety, Tolerability and Pharmacodynamics of Inhaled BAY1237592 Recruiting NCT03754660 Phase 1 BAY1237592;PH-monotherapy;PH-combination therapy
26 A Phase I Study of the Safety and Feasibility of Central Intravenous Delivery of Allogeneic Human Cardiosphere-Derived Stem Cells in Patients With Pulmonary Arterial Hypertension ALPHA Trial Recruiting NCT03145298 Phase 1
27 Inspiratory Muscle Training in Patients With Chronic Thromboembolic Pulmonary Hypertension: a Randomized Controlled Trial Unknown status NCT03102294
28 Incidence of CTEPH in Dependence of Thrombus Location in Patients With Acute Pulmonary Embolism and Index Fibrinolysis Unknown status NCT01672203
29 Prospective Registry to Evaluate the Effective Incidence of Chronic Thromboembolic Pulmonary Hypertension in Germany Unknown status NCT02660463
30 Long-term Right Ventricular Resynchronization Therapy for Chronic Thromboembolic Pulmonary Hypertension Unknown status NCT01163422
31 Assessment of Safety and Efficacy of Balloon Pulmonary Angioplasty in Non-operable CTEPH Patients Unknown status NCT02964390
32 Incidence of Latent Pulmonary Hypertension in Patients With Chronic Thromboembolic Pulmonary Hypertension After Endarterectomy and Influence of Exercise and Respiratory Therapy Unknown status NCT00477724
33 Gene Mutations in Secondary Pulmonary Hypertension Unknown status NCT00348803
34 Exhaled Breath Olfactory Signature of Pulmonary Arterial Hypertension Detected by an Artificial Nose: A Clinical Validation Study Unknown status NCT02782026
35 Epidemiological Study of Chronic Thromboembolic Pulmonary Hypertension in China Unknown status NCT01717092
36 Three-dimensional Echocardiographic Assessment of Right Ventricular Function in Patients Undergoing Pulmonary Endarterectomy Unknown status NCT02426203
37 Effect of Endothelin Receptor Antagonist Bosentan in Glucose Metabolism of the Myocardium and Coronary Dependant Endothelial Vasoreactivity Measured by 18F-FDG PET / CT and 82Rb PET / CT in Patients With PAH or CTEPH Unknown status NCT02970851
38 Retrospective Chart Review of Patients With PAH or Inoperable/Persistent/Recurrent CTEPH Who Transition Their PH Treatment to Adempas Completed NCT02545465 Riociguat (Adempas, BAY63-2521)
39 Identification Of The Predictive Angiographic And Computed Tomographic (CT) Criteria Of The Success Of The Thromboendarterectomy In Chronic Pulmonary Hypertension Completed NCT00657722
40 (e-MOTION PH) Electronic - Activity Level Monitoring Pilot in Pulmonary Hypertension Completed NCT02536534
41 Identification of CTEPH on Standard Computerised Tomography Pulmonary Angiography Performed in the Work-up of Suspected Pulmonary Embolism Completed NCT03083093
42 A Prospective Single Blind Controlled Study to Assess the Efficacy of a Lung Protective Ventilation Strategy in the Prevention of Reperfusion Lung Injury Following PTE Completed NCT00747045
43 Study on the Clinical Course Of Pulmonary Embolism Completed NCT01781858
44 Smoking: a Risk Factor for Pulmonary Arterial Hypertension? A D-A-CH Pulmonary Hypertension Study (Germany- Austria - Switzerland) Completed NCT01484899
45 Evaluation of Pulmonary Perfusion Heterogeneity in Patients With Chronic Thromboembolic Pulmonary Hypertension Using Functional PET Imaging Completed NCT02114047
46 Efficacy of Medical Therapy for Pulmonary Arterial and Inoperable Chronic Thromboembolic Pulmonary Hypertension in a Real Life Setting Completed NCT03198910
47 The Effect of Adding Exercise Training to Optimal Therapy in Pulmonary Arterial Hypertension Completed NCT02961023
48 Auto-immunity and Prognosis of Pulmonary Arterial Hypertension Completed NCT01208792
49 Multi-Screen Electronic Alert for Venous Thromboembolism Prevention Completed NCT00550082
50 Acute Exposure to Hypoxia in Precapillary Pulmonary Hypertension: Physiological and Clinical Effects at Rest and During Exercise Completed NCT03592927

Search NIH Clinical Center for Chronic Thromboembolic Pulmonary Hypertension

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Riociguat

Genetic Tests for Chronic Thromboembolic Pulmonary Hypertension

Anatomical Context for Chronic Thromboembolic Pulmonary Hypertension

MalaCards organs/tissues related to Chronic Thromboembolic Pulmonary Hypertension:

41
Lung, Heart, Endothelial, Testes, Brain, Smooth Muscle, Neutrophil

Publications for Chronic Thromboembolic Pulmonary Hypertension

Articles related to Chronic Thromboembolic Pulmonary Hypertension:

(show top 50) (show all 1869)
# Title Authors PMID Year
1
The Pathobiology of Chronic Thromboembolic Pulmonary Hypertension. 38 6
27571003 2016
2
Exertion during a hypoxia altitude simulation test helps identify potential cardiac decompensation. 38
31285824 2019
3
Clinical usefulness of right ventricular 3D area strain in the assessment of treatment effects of balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension: comparison with 2D feature-tracking MRI. 38
30790024 2019
4
IodiNe Subtraction mapping in the diagnosis of Pulmonary chronIc thRomboEmbolic disease (INSPIRE): Rationale and methodology of a cross-sectional observational diagnostic study. 38
31388600 2019
5
Impact of pulmonary endarterectomy on pulmonary arterial wave propagation and reservoir function. 38
31225986 2019
6
Indications and potential pitfalls of anticoagulants in pulmonary hypertension: Would DOACs become a better option than VKAs? 38
31113643 2019
7
Paradoxical Cerebral Embolism as Initial Manifestation of Chronic Thromboembolic Pulmonary Hypertension: A Case Report. 38
31253482 2019
8
Meta-analysis of use of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. 38
30850238 2019
9
Long-term changes of resting and exercise right ventricular systolic performance in patients with chronic thromboembolic pulmonary hypertension following pulmonary thromboendarterectomy - A two-dimensional and three-dimensional echocardiographic study. 38
31424115 2019
10
Effect of domiciliary oxygen therapy on exercise capacity and quality of life in patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomised, placebo-controlled trial. 38
31073087 2019
11
Effectiveness of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension despite having lesion types suitable for surgical treatment. 38
31427133 2019
12
Use of direct oral anticoagulants prevents increase in pulmonary vascular resistance and incidence of clinical worsening in patients with chronic thromboembolic pulmonary hypertension. 38
31200342 2019
13
Potential Involvement of Osteopontin in Inflammatory and Fibrotic Processes in Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension. 38
31183846 2019
14
Balloon pulmonary angioplasty vs riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension: A systematic review and meta-analysis. 38
31188483 2019
15
Electrocardiographic Criteria of Right Ventricular Hypertrophy in Patients with Chronic Thromboembolic Pulmonary Hypertension after Balloon Pulmonary Angioplasty. 38
30996169 2019
16
Balloon Pulmonary Angioplasty for the Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension: Single-Center Experience with Low Initial Complication Rate. 38
31349979 2019
17
Should Perfusion Scintigraphy Be Performed to Follow Patients with Acute Pulmonary Embolism? If So, When? 38
31123098 2019
18
In vitro assessment of P-gp and BCRP transporters-mediated drug-drug interactions of riociguat with direct oral anticoagulants. 38
31411766 2019
19
Impaired Cardiac Reserve and Abnormal Vascular Load Limit Exercise Capacity in Chronic Thromboembolic Disease. 38
30219401 2019
20
Balloon pulmonary angioplasty for symptomatic chronic thromboembolic disease without pulmonary hypertension at rest. 38
31060757 2019
21
Commentary: Chronic thromboembolic pulmonary hypertension in Austria and Japan: The Sound of Music meets Madame Butterfly. 38
30798956 2019
22
Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. 38
31103383 2019
23
Not Quite Chronic Thromboembolic Pulmonary Hypertension But More Than a SOB Story. 38
30219406 2019
24
Predicting survival for non-operative chronic thromboembolic pulmonary hypertension: Practice can make perfect. 38
31352999 2019
25
Diaphragm Function Does Not Independently Predict Exercise Intolerance in Patients with Precapillary Pulmonary Hypertension After Adjustment for Right Ventricular Function. 38
31427479 2019
26
Chronic thromboembolic pulmonary hypertension in Austria and Japan. 38
31084984 2019
27
Long term prognosis of acute pulmonary embolism. 38
31326193 2019
28
Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial. 38
30564950 2019
29
Usefulness of ventilatory gas analysis for the non-invasive evaluation of the severity of chronic thromboembolic pulmonary hypertension. 38
31350036 2019
30
miRNA-PDGFRB/HIF1A-lncRNA CTEPHA1 Network Plays Important Roles in the Mechanism of Chronic Thromboembolic Pulmonary Hypertension. 38
31204374 2019
31
Usefulness of standard computed tomography pulmonary angiography performed for acute pulmonary embolism for identification of chronic thromboembolic pulmonary hypertension: results of the InShape III study. 38
30962147 2019
32
Physical activity in incident patients with pulmonary arterial and chronic thromboembolic hypertension. 38
31263960 2019
33
A meta-analysis of randomized controlled trials in targeted treatments of chronic thromboembolic pulmonary hypertension. 38
31059198 2019
34
Advanced interstitial lung fibrosis with emphysema and pulmonary hypertension with no evidence for interstitial lung disease on high resolution CT. 38
30729872 2019
35
Heart Rhythm Complexity Impairment in Patients with Pulmonary Hypertension. 38
31341216 2019
36
Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension incidence in Latvia in 2018. 38
31101467 2019
37
Chronic thromboembolic and pulmonary arterial hypertension share right ventricular and pulmonary artery CMR features. 38
31080042 2019
38
Non-invasive screening using ventilatory gas analysis to distinguish between chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. 38
31261445 2019
39
Cross-cultural adaptation of the Cambridge Pulmonary Hypertension Outcome Review for use in patients with pulmonary hypertension in Colombia. 38
31365733 2019
40
Development of renal function during staged balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension. 38
30987470 2019
41
Protective role of endothelial progenitor cells stimulated by riociguat in chronic thromboembolic pulmonary hypertension. 38
31337550 2019
42
Balloon pulmonary angioplasty attenuates sleep apnea in patients with chronic thromboembolic pulmonary hypertension. 38
31029378 2019
43
A Case of Chronic Thromboembolic Pulmonary Hypertension in a High-Altitude Dweller. 38
31264887 2019
44
Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension - A Systematic Review and Meta-Analysis. 38
31231116 2019
45
Balloon Pulmonary Angioplasty (Percutaneous Transluminal Pulmonary Angioplasty) for Chronic Thromboembolic Pulmonary Hypertension: A Japanese Perspective. 38
31103538 2019
46
Tackling the right ventricle in chronic thromboembolic pulmonary hypertension. 38
31339590 2019
47
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. 38
31229228 2019
48
Evaluation of a newly developed 2D parametric parenchymal blood flow technique with an automated vessel suppression algorithm in patients with chronic thromboembolic pulmonary hypertension undergoing balloon pulmonary angioplasty. 38
30890260 2019
49
Commentary on: evaluation of a newly developed 2D parametric parenchymal blood flow technique with an automated vessel suppression algorithm in patients with chronic thromboembolic pulmonary hypertension undergoing balloon pulmonary angioplasty. 38
30910170 2019
50
Prevalence of antiphospholipid (aPL) antibodies among patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. 38
30603858 2019

Variations for Chronic Thromboembolic Pulmonary Hypertension

Expression for Chronic Thromboembolic Pulmonary Hypertension

Search GEO for disease gene expression data for Chronic Thromboembolic Pulmonary Hypertension.

Pathways for Chronic Thromboembolic Pulmonary Hypertension

GO Terms for Chronic Thromboembolic Pulmonary Hypertension

Cellular components related to Chronic Thromboembolic Pulmonary Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.43 NPPB FGA F2 EDN1 CRP CPB2
2 extracellular space GO:0005615 9.17 NPPB FGA F2 EDN1 CRP CPB2

Biological processes related to Chronic Thromboembolic Pulmonary Hypertension according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.63 NPPB F2 EDN1
2 blood coagulation GO:0007596 9.61 FGA F2 CPB2
3 regulation of blood pressure GO:0008217 9.51 NPPB EDN1
4 positive regulation of endothelial cell migration GO:0010595 9.49 EDN1 BMPR2
5 acute-phase response GO:0006953 9.48 F2 CRP
6 regulation of blood vessel size GO:0050880 9.4 NPPB EDN1
7 positive regulation of urine volume GO:0035810 9.37 NPPB EDN1
8 positive regulation of renal sodium excretion GO:0035815 9.32 NPPB EDN1
9 negative regulation of fibrinolysis GO:0051918 9.26 F2 CPB2
10 body fluid secretion GO:0007589 9.16 NPPB EDN1
11 hemostasis GO:0007599 9.13 FGA F2 CPB2
12 fibrinolysis GO:0042730 8.8 FGA F2 CPB2

Molecular functions related to Chronic Thromboembolic Pulmonary Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 8.92 NPPB FGA F2 EDN1

Sources for Chronic Thromboembolic Pulmonary Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....